Claudio Cesar Cirne-Santos
Oswaldo Cruz Foundation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Claudio Cesar Cirne-Santos.
Memorias Do Instituto Oswaldo Cruz | 2008
Jadel M. Kratz; Carla Regina Andrighetti-Fröhner; Deise Juliana Kolling; Paulo César Leal; Claudio Cesar Cirne-Santos; Rosendo A. Yunes; Ricardo José Nunes; Edward Trybala; Tomas Bergström; Izabel C.P.P. Frugulhetti; Célia Regina Monte Barardi; Cláudia Maria Oliveira Simões
The synthetic n-alkyl esters of gallic acid (GA), also known as gallates, especially propyl, octyl and dodecyl gallates, are widely employed as antioxidants by food and pharmaceutical industries. The inhibitory effects of GA and 15 gallates on Herpes Simplex Virus type 1 (HSV-1) and Human Immunodeficiency Virus (HIV-1) replication were investigated here. After a preliminary screening of these compounds, GA and pentyl gallate (PG) seemed to be the most active compounds against HSV-1 replication and their mode of action was characterized through a set of assays, which attempted to localize the step of the viral multiplication cycle where impairment occurred. The detected anti-HSV-1 activity was mediated by the inhibition of virus attachment to and penetration into cells, and by virucidal properties. Furthermore, an anti-HIV-1 activity was also found, to different degrees. In summary, our results suggest that both compounds could be regarded as promising candidates for the development of topical anti-HSV-1 agents, and further studies concerning the anti-HIV-1 activity of this group of molecules are merited.
PLOS Neglected Tropical Diseases | 2012
Deivid Costa Soares; Teresa Cristina Calegari-Silva; Ulisses G. Lopes; Valéria Laneuville Teixeira; Izabel Christina Nunes de Palmer Paixão; Claudio Cesar Cirne-Santos; Dumith Chequer Bou-Habib; Elvira M. Saraiva
Background Chemotherapy for leishmaniasis, a disease caused by Leishmania parasites, is expensive and causes side effects. Furthermore, parasite resistance constitutes an increasing problem, and new drugs against this disease are needed. In this study, we examine the effect of the compound 8,10,18-trihydroxy-2,6-dolabelladiene (Dolabelladienetriol), on Leishmania growth in macrophages. The ability of this compound to modulate macrophage function is also described. Methodology/Principal Findings Leishmania-infected macrophages were treated with Dolabelladienetriol, and parasite growth was measured using an infectivity index. Nitric oxide (NO), TNF-α and TGF-β production were assayed in macrophages using specific assays. NF-kB nuclear translocation was analyzed by western blot. Dolabelladienetriol inhibited Leishmania in a dose-dependent manner; the IC50 was 44 µM. Dolabelladienetriol diminished NO, TNF-α and TGF-β production in uninfected and Leishmania-infected macrophages and reduced NF-kB nuclear translocation. Dolabelladienetriol inhibited Leishmania infection even when the parasite growth was exacerbated by either IL-10 or TGF-β. In addition, Dolabelladienetriol inhibited Leishmania growth in HIV-1-co-infected human macrophages. Conclusion Our results indicate that Dolabelladienetriol significantly inhibits Leishmania in macrophages even in the presence of factors that exacerbate parasite growth, such as IL-10, TGF-β and HIV-1 co-infection. Our results suggest that Dolabelladienetriol is a promising candidate for future studies regarding treatment of leishmaniasis, associated or not with HIV-1 infection.
Marine Drugs | 2014
Alonso Pardo-Vargas; Ingrid de Barcelos Oliveira; Paulo Roberto Soares Stephens; Claudio Cesar Cirne-Santos; Izabel Christina Nunes de Palmer Paixão; Freddy A. Ramos; Carlos Jiménez; Jaime Rodríguez; Jackson A. L. C. Resende; Valéria Laneuville Teixeira; Leonardo Castellanos
The marine brown alga Dictyota pfaffii from Atol das Rocas, in Northeast Brazil is a rich source of dolabellane diterpene, which has the potential to be used in future antiviral drugs by inhibiting reverse transcriptase (RT) of HIV-1. Reexamination of the minor diterpene constituents yielded three new dolabellane diterpenes, (1R*,2E,4R*,7S,10S*,11S*,12R*)10,18-diacetoxy-7-hydroxy-2,8(17)-dolabelladiene (1), (1R*,2E,4R*,7R*,10S*,11S*,12R*)10,18-diacetoxy-7-hydroxy-2,8(17)-dolabelladiene (2), (1R*,2E,4R*,8E,10S*,11S,12R*)10,18-diacetoxy-7-hydroxy-2,8-dolabelladiene (3), termed dolabelladienols A–C (1–3) respectively, in addition to the known dolabellane diterpenes (4–6). The elucidation of the compounds 1–3 was assigned by 1D and 2D NMR, MS, optical rotation and molecular modeling, along with the relative configuration of compound 4 and the absolute configuration of 5 by X-ray diffraction. The potent anti-HIV-1 activities displayed by compounds 1 and 2 (IC50 = 2.9 and 4.1 μM), which were more active than even the known dolabelladienetriol 4, and the low cytotoxic activity against MT-2 lymphocyte tumor cells indicated that these compounds are promising anti-HIV-1 agents.
Current HIV Research | 2008
Thiago Moreno L. Souza; Claudio Cesar Cirne-Santos; Diego Q. Rodrigues; Celina Monteiro Abreu; Amilcar Tanuri; Vitor F. Ferreira; Isakelly P. Marques; Maria Cecília B. V. de Souza; Carlos Frederico Leite Fontes; Izabel Chistina de Palmer Paixao Frugulhetti; Dumith Chequer Bou-Habib
We describe in this paper that the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl)-quinoline-3-carboxylic acid (compound A) inhibits the HIV-1 replication in human primary cells. We initially observed that compound A inhibited HIV-1 infection in peripheral blood mononuclear cells (PBMCs) in a dose-dependent manner, resulting in an EC(50) of 1.5 +/- 0.5 microM and in a selective index of 1134. Likewise, compound A blocked HIV-1(BA-L) replication in macrophages in a dose-dependent manner, with an EC(50) equal to 4.98 +/- 0.9 microM. The replication of HIV-1 isolates from subtypes C and F was also inhibited by compound A with the same efficiency. Compound A inhibited an early event of the HIV-1 replicative cycle, since it prevented viral DNA synthesis in PBMCs exposed to HIV-1. Kinetic assays demonstrated that compound A inhibits the HIV-1 enzyme reverse transcriptase (RT) in dose-dependent manner, with a K(I) equal to 0.5 +/- 0.04 microM. Using a panel of HIV-1 isolates harboring NNRTI resistance mutations, we found a low degree of cross-resistance between compound A and clinical available NNRTIs. In addition, compound A exhibited additive effects with the RT inhibitors AZT and nevirapine, and synergized with the protease inhibitor atazanavir. Our results encourage continuous studies about the kinetic impact of compound A towards different catalytic forms of RT enzyme, and suggest that our nucleoside represents a promising molecule for future antiretroviral drug design.
Bioorganic & Medicinal Chemistry Letters | 2014
Alonso Pardo-Vargas; Freddy A. Ramos; Claudio Cesar Cirne-Santos; Paulo Roberto Soares Stephens; Izabel Christina Nunes de Palmer Paixão; Valéria Laneuville Teixeira; Leonardo Castellanos
Research on dolabellane diterpenes of brown algae Dictyota spp. has shown that these diterpenoids have strong anti-HIV-1 activity, but there are not data about antiviral activity of dolabellane diterpenes isolated from octocorals, which are antipodes of those isolated from the brown algae. Dolabellanes 13-keto-1(R),11(S)-dolabella-3(E),7(E),12(18)-triene (1) and β-Araneosene (2) were isolated from the Caribbean octocoral Eunicea laciniata, and both showed low anti-HIV-1 activity and low toxicity. Since it was shown that oxygenated dolabellanes from algae have better anti-HIV-1 activity, in this work some derivatives of the main dolabellane of E. laciniata1 were obtained by epoxidation (3), epoxide opening (4), and allylic oxidation (5). The derivatives showed significant improvement in the anti-HIV-1potency (100-fold), being compounds 3 and 5 the most active ones. Their high antiviral activities, along with their low cytotoxicity, make them promissory antiviral compounds; and it is worth noting that the absolute configuration at the ring junction in the dolabellane skeleton does not seem to be determinant in the antiviral potency of these diterpeneoids.
Antiviral Research | 2008
Claudio Cesar Cirne-Santos; Thiago Moreno L. Souza; Valéria Laneuville Teixeira; Carlos Frederico Leite Fontes; Moacyr Alcoforado Rebello; Luiz Roberto Castello-Branco; Celina Monteiro Abreu; Amilcar Tanuri; Izabel C.P.P. Frugulhetti; Dumith Chequer Bou-Habib
Planta Medica | 2006
Claudio Cesar Cirne-Santos; Valéria Laneuville Teixeira; Luiz Roberto Castello-Branco; Izabel C.P.P. Frugulhetti; Dumith Chequer Bou-Habib
Bioorganic & Medicinal Chemistry | 2009
Fernanda da C. Santos; Paula A. Abreu; Helena C. Castro; Izabel Cnp Paixão; Claudio Cesar Cirne-Santos; Viveca Giongo; Juliana E. Barbosa; Bruno R. Simonetti; Valéria Garrido; Dumith Chequer Bou-Habib; David de O. Silva; Pedro N. Batalha; Jairo R. Temerozo; Thiago Ml Souza; Christiane M. Nogueira; Anna C. Cunha; Carlos Rangel Rodrigues; Vitor F. Ferreira; Maria Cecília B. V. de Souza
Planta Medica | 2004
Edinete Melo da Silva; Claudio Cesar Cirne-Santos; Izabel C.P.P. Frugulhetti; Bernardo Galvão-Castro; Elvira M. Saraiva; Martin E. Kuehne; Dumith Chequer Bou-Habib
Journal of Applied Phycology | 2016
Caroline de Souza Barros; Claudio Cesar Cirne-Santos; Valéria Garrido; Ingrid Barcelos; Paulo Roberto Soares Stephens; Viveca Giongo; Valéria Laneuville Teixeira; Izabel Christina Nunes de Palmer Paixão